RankAlpha logo
Back to Rankings

OLMA

OlemaC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The constructive case is straightforward: the company has cash runway into mid-2028, OP-3136 data are due in Q2 2026, and the core equity unlock is OPERA-01 top-line data in fall 2026 with management already outlining a possible 2027 NDA and late-2027 launch path if the study works [#10-K-2026-03-16][#8-K-2026-03-16].
Posture
Mixed
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bearish as of 2026-06-02.
What can break
Cash runway is projected through mid-2028, but higher trial/commercial-prep spending could pull financing needs forward if timelines slip.
Momentum
9
Value
41
Sentiment
100
Setup hits (3d)
1 · Net Bearish
AI TargetsBase $17.00 · Bull $26.00 · Bear $10.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bearish
Target $45.82
Why
Momentum9 · Δ7d -3.1
Value41 · Δ7d +0.1
Sentiment100 · Δ7d +14.2
So what
Balanced signals (Net Bearish). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
9
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.1
Δ21d
-5.1
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendImproving
Δ7d
+14.2
Δ21d
+29.6
Why this grade

Composite grade C. Momentum 9.3 / Value 41.1 / Sentiment 100.0

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.11B
Beta
1.91
Shares Out
78.66M
P/E (TTM) · Derived
-6.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-8.70
Rev YoY
-
EPS YoY
+18.4%
Gross Margin
-
Op Margin
-
Net Debt
-$434.09M
Current Ratio
8.03
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology